Clinical and safety outcomes associated with aristolochic acid exposure: a systematic review and meta-analysis

Ting Cui1,2, Shumei Che1, Xingxu Yan1

  • 1School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, China.

PubMed

Insights

Aristolochic acid (AA) exposure significantly increases the risk of overall disease, kidney disease, urinary tract cancer, and liver cancer. This meta-analysis provides evidence for AA-related health risks.

Area of Science:

  • Toxicology
  • Oncology
  • Nephrology

Background:

  • Aristolochic acid (AA) is a known nephrotoxin and carcinogen.
  • Previous studies indicate a link between AA exposure and various diseases, including kidney disease, liver cancer, and urinary tract cancer (UTC).
  • A systematic analysis integrating these findings is lacking.

Purpose of the Study:

  • To systematically analyze and integrate existing evidence on the association between aristolochic acid (AA) exposure and the risk of overall disease and specific AA-related cancers.
  • To provide a comprehensive overview of AA's safety outcomes.

Main Methods:

  • A systematic literature search was conducted across major databases (PubMed, EMBASE, Web of Science, Cochrane Library) up to April 2024.
  • Meta-analysis was performed to calculate odds ratios (OR) and confidence intervals (CI) for the association between AA exposure and various diseases.

Main Results:

  • AA exposure was significantly associated with an increased incidence of overall AA-related disease (OR: 1.289, 95% CI: 1.183-1.404).
  • Significant associations were found for kidney disease (OR: 1.279, 95% CI: 1.029-1.590), UTC (OR: 1.842, 95% CI: 1.376-2.465), and liver cancer (OR: 1.146, 95% CI: 1.040-1.262).
  • No significant association was observed for brain disease (OR: 1.161, 95% CI: 0.989-1.362).

Conclusions:

  • Aristolochic acid exposure is a significant risk factor for kidney disease, urinary tract cancer, and liver cancer.
  • This systematic review underscores the importance of understanding and mitigating AA exposure for public health.
  • Findings support the development of targeted prevention strategies and improved clinical management for AA-related conditions.

Related Concept Videos

Toxic Reactions: Overview01:26

Toxic Reactions: Overview

When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
938
Types of Toxins01:36

Types of Toxins

Humans continually engage with an environment rich in potentially harmful chemicals. These are introduced to our bodies through inhalation, ingestion, or skin contact. These chemicals exist in various forms, such as air and environmental pollutants, agricultural chemicals, organic solvents, and heavy metals.
Air pollutants, primarily gases, pose significant threats to respiratory health, leading to conditions like hypoxia, lung cancer, and in extreme cases, death.
Environmental pollutants like...
1.6K
Effects of Chemicals: Overview01:27

Effects of Chemicals: Overview

Drugs, encompassing various chemical compounds from natural sources, lab synthesis, or genetic engineering, elicit different biological responses in living organisms. Some of these responses are desirable or therapeutic, while others are undesirable. The primary goal of administering a drug is to achieve a therapeutic effect, that is, to address a specific disease or health condition. Any concurrent effects outside of this therapeutic outcome are considered undesirable. These undesirable...
1.2K
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K
Local Anesthetics: Adverse Effects01:12

Local Anesthetics: Adverse Effects

While local anesthetics are generally safe and well-tolerated, they can occasionally cause adverse effects that vary in severity. Local anesthetics can induce toxicity at two distinct levels. They can either produce local effects through direct contact with the neural elements or be absorbed into the bloodstream from the injection site, leading to systemic effects.
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
386
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
115